ポイントオブケア分子診断市場：世界の産業規模、シェア、動向、機会、予測、技術別、用途別、検査場所別、エンドユーザー別、地域別、競合別、2019年～2029年

ポイントオブケア分子診断の世界市場規模は2023年に20億7,000万米ドルとなり、2029年までの予測期間のCAGRは10.93%で堅調な成長が見込まれます。

ポイントオブケア分子診断（POC MDx）とは、患者の診療現場またはその近くで実施され、短期間で迅速かつ実用的な結果を提供する診断検査を指します。これらの検査は、特定の病原体、遺伝子変異、または疾患のバイオマーカーに関連する核酸（DNAまたはRNA）を検出・分析する分子技術を利用します。POC分子診断法は迅速な検査が可能であり、従来の検査室ベースの検査法では結果が出るまでに数日を要する場合があるのに比べ、数分から数時間で結果が得られます。この迅速な結果によって、ヘルスケアプロバイダーは即座に治療を決定し、患者管理を最適化し、感染対策をより効果的に実施することができます。POC分子診断は、ポリメラーゼ連鎖反応（PCR）、核酸増幅検査（NAAT）、ループ媒介等温増幅法（LAMP）、CRISPRベースのアッセイなどの分子技術を活用し、標的核酸配列を高感度かつ特異的に増幅・検出します。これらの技術により、様々な疾患や状態に関連する病原体、遺伝子変異、バイオマーカーの検出が可能となります。多くのPOC分子診断装置は、サンプル調製、核酸抽出、増幅、検出の各工程を1台の装置またはカートリッジに統合したsample-to-answerプラットフォームとして設計されています。このような統合プラットフォームは、検査プロセスを合理化し、作業時間を最小限に抑え、汚染のリスクを低減するため、検査室のインフラや技術的専門知識が限られているポイント・オブ・ケア環境での使用に最適です。

分子生物学、マイクロ流体工学、核酸増幅技術の進歩により、高感度で特異性が高く、使いやすいPOC分子診断装置が開発されています。これらの技術革新は、ポイントオブケア検査の能力を拡大し、診断結果の正確性と信頼性を向上させています。世界の動向として、特に十分なサービスを受けていない地域や遠隔地における診断サービスへの迅速なアクセスの必要性から、検査の分散化とポイントオブケア診断が進んでいます。ポイントオブケア分子診断は、中央集中型の検査施設を不要にし、診療所、救急部、地域環境において、患者のベッドサイドでの検査を可能にします。ポイントオブケア分子診断は、数分から数時間以内の迅速な検査結果を提供し、タイムリーな診断と治療の決定を可能にします。ポイント・オブ・ケアで即座に結果が得られることは、感染症の管理、患者ケアの最適化、疾病伝播リスクの低減に特に有用です。

主な市場促進要因

分子診断技術の進歩

分散型検査へのシフトの高まり

個別化医療への需要の高まり

主な市場課題

品質管理と保証

インフラと接続性

主な市場動向

小型化と携帯性

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のポイントオブケア分子診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（PCRベース、遺伝子配列ベース、ハイブリダイゼーションベース、マイクロアレイベース）
  • 用途別（感染症、腫瘍学、血液学、出生前検査、内分泌学、その他）
  • 検査場所別（OTC、POC）
  • エンドユーザー別（分散型ラボ、病院、在宅ケア、入居型介護ヘルスケア施設、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ

第6章 北米のポイントオブケア分子診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 検査場所別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のポイントオブケア分子診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 検査場所別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のポイントオブケア分子診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 検査場所別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のポイントオブケア分子診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 検査場所別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのポイントオブケア分子診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 検査場所別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のポイントオブケア分子診断市場：SWOT分析

第14章 競合情勢

• Siemens Healthineers AG
• Quidel Corporation
• F. Hoffman-La Roche Ltd.
• Danaher Corporation
• Beckton & Dickinson Company
• Trinity Biotech plc
• Thermo Fisher Scientific Inc
• bioMerieux S.A.
• DiaSorin S.p.A
• AccuBioTech Co., Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Point-Of-Care Molecular Diagnostics Market was valued at USD 2.07 billion in 2023 and will see an robust growth in the forecast period at a CAGR of 10.93% through 2029. Point-of-care molecular diagnostics (POC MDx) refers to diagnostic tests that are performed at or near the site of patient care, providing rapid and actionable results within a short timeframe. These tests utilize molecular techniques to detect and analyze nucleic acids (DNA or RNA) associated with specific pathogens, genetic variations, or biomarkers of disease. POC molecular diagnostics offer rapid testing capabilities, providing results in minutes to hours compared to traditional laboratory-based methods, which may take days to deliver results. This rapid turnaround time enables healthcare providers to make immediate treatment decisions, optimize patient management, and implement infection control measures more effectively. POC molecular diagnostics leverage molecular techniques such as polymerase chain reaction (PCR), nucleic acid amplification tests (NAATs), loop-mediated isothermal amplification (LAMP), and CRISPR-based assays to amplify and detect target nucleic acid sequences with high sensitivity and specificity. These techniques enable the detection of pathogens, genetic mutations, and biomarkers associated with various diseases and conditions. Many POC molecular diagnostic devices are designed as sample-to-answer platforms, integrating sample preparation, nucleic acid extraction, amplification, and detection steps into a single instrument or cartridge. These integrated platforms streamline the testing process, minimize hands-on time, and reduce the risk of contamination, making them ideal for use in point-of-care settings with limited laboratory infrastructure and technical expertise.

Advances in molecular biology, microfluidics, and nucleic acid amplification technologies have led to the development of highly sensitive, specific, and user-friendly point-of-care molecular diagnostic devices. These technological innovations expand the capabilities of point-of-care testing and improve the accuracy and reliability of diagnostic results. There is a global trend towards decentralized testing and point-of-care diagnostics, driven by the need for rapid access to diagnostic services, especially in underserved or remote areas. Point-of-care molecular diagnostics eliminates the need for centralized laboratory facilities and enable testing to be performed at the patient's bedside, in clinics, emergency departments, and community settings. Point-of-care molecular diagnostics offer rapid test results, often within minutes to hours, enabling timely diagnosis and treatment decisions. The ability to obtain immediate results at the point of care is particularly valuable for managing infectious diseases, optimizing patient care, and reducing the risk of disease transmission.

Key Market Drivers

Advancements in Molecular Diagnostic Technologies

Next-generation sequencing technologies have transformed genomic analysis by enabling high-throughput sequencing of DNA and RNA molecules. NGS platforms offer unparalleled sequencing depth, resolution, and scalability, facilitating a wide range of applications such as whole-genome sequencing, targeted gene sequencing, transcriptomics, and metagenomics. Digital PCR technologies enable precise quantification of nucleic acid targets by partitioning DNA or RNA samples into thousands of individual reactions. Digital PCR offers superior sensitivity, accuracy, and reproducibility compared to conventional PCR methods, making it ideal for detecting rare mutations, measuring gene expression levels, and quantifying viral load in clinical samples. Isothermal amplification techniques, such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA), allow rapid amplification of nucleic acids at a constant temperature without the need for thermal cycling. These isothermal amplification methods are well-suited for point-of-care diagnostics, field testing, and resource-limited settings due to their simplicity, speed, and robustness.

CRISPR-based diagnostic technologies leverage the CRISPR-Cas system for nucleic acid detection and gene editing. CRISPR-based diagnostics offer rapid and specific detection of target sequences with high sensitivity and specificity, enabling applications such as pathogen detection, genotyping, and mutation analysis. CRISPR-based diagnostics hold promise for point-of-care testing and precision medicine. Microfluidic-based diagnostic platforms integrate microscale fluid handling and analytical techniques for performing complex molecular assays in miniaturized devices. Microfluidic systems offer advantages such as reduced sample volumes, rapid reaction kinetics, and automation capabilities, making them suitable for point-of-care diagnostics, high-throughput screening, and multiplexed assays.

Biosensors and nanotechnology-based platforms enable label-free detection and quantification of biomolecules with high sensitivity and specificity. Biosensors utilize various transduction mechanisms, including optical, electrochemical, and mechanical signals, for real-time and multiplexed detection of nucleic acids, proteins, and small molecules. Nanotechnology enhances the performance of biosensors by providing nanomaterials with unique properties such as enhanced surface area, biocompatibility, and signal amplification. Artificial intelligence (AI) algorithms and machine learning techniques are increasingly applied to analyze large-scale molecular data generated from diagnostic tests, omics studies, and clinical trials. AI-driven data analytics enable rapid interpretation of complex molecular profiles, prediction of disease outcomes, identification of therapeutic targets, and personalized treatment recommendations, thereby improving patient care and clinical decision-making. This factor will help in the development of the Global Point-Of-Care Molecular Diagnostics Market.

Increasing Shift Towards Decentralized Testing

POC molecular diagnostics offer the advantage of providing rapid test results, often within minutes to hours, compared to traditional laboratory-based testing methods that may take days to deliver results. Timely diagnosis enables healthcare providers to make prompt treatment decisions, leading to improved patient outcomes, particularly in acute conditions such as infectious diseases. POC molecular diagnostics bring diagnostic testing directly to the patient's bedside, clinic, or community setting, eliminating the need for samples to be sent to centralized laboratories. This accessibility and convenience reduce the time and logistical barriers associated with traditional laboratory testing, particularly in remote or resource-limited areas where access to centralized healthcare facilities may be limited. By bypassing the need for sample transportation and centralized laboratory processing, POC molecular diagnostics offer significantly reduced turnaround times for test results. This rapid turnaround time is crucial for managing infectious disease outbreaks, implementing timely interventions, and reducing the risk of disease transmission in healthcare settings and communities.

POC molecular diagnostics empower healthcare providers to make informed treatment decisions at the point of care, based on real-time diagnostic information. This immediate feedback loop enhances clinical decision-making, enables targeted therapy, and supports precision medicine approaches tailored to individual patient needs and disease characteristics. POC molecular diagnostics facilitate rapid screening, diagnosis, and monitoring of infectious diseases, chronic conditions, and therapeutic responses. By providing actionable diagnostic information at the point of care, POC molecular diagnostics enable more proactive and personalized patient management strategies, leading to better disease management and treatment outcomes. POC molecular diagnostics play a critical role in public health preparedness and emergency response efforts, particularly during pandemics, outbreaks, and natural disasters. These diagnostics enable rapid screening, surveillance, and containment of infectious diseases, helping to identify and isolate cases, track transmission chains, and inform public health interventions in real time. This factor will pace up the demand of the Global Point-Of-Care Molecular Diagnostics Market.

Growing Demand for Personalized Medicine

Personalized medicine aims to customize medical care and treatment plans based on individual patient characteristics, including genetic makeup, biomarker profiles, and disease susceptibility. POC molecular diagnostics provide rapid and accurate identification of genetic variations, biomarkers, and therapeutic targets, enabling healthcare providers to tailor treatment approaches to each patient's specific needs and disease characteristics. POC molecular diagnostics enable rapid genetic testing and risk assessment for a wide range of conditions, including genetic disorders, hereditary diseases, and cancer predisposition syndromes. By detecting genetic mutations, single nucleotide polymorphisms (SNPs), and other genetic markers at the point of care, POC molecular diagnostics empower patients and healthcare providers to make informed decisions about disease prevention, screening, and management. Pharmacogenomic testing using POC molecular diagnostics helps predict individual responses to medications and optimize drug therapy regimens based on genetic factors. By identifying genetic variations that influence drug metabolism, efficacy, and toxicity, POC molecular diagnostics enable personalized prescribing practices, minimize adverse drug reactions, and enhance treatment outcomes for patients.

POC molecular diagnostics serve as companion diagnostic tests for targeted therapies and precision medicine approaches. These tests help identify patients who are most likely to benefit from specific therapies, such as targeted cancer treatments or immunotherapies, based on their molecular profiles and biomarker expression patterns. POC companion diagnostics enable timely treatment decisions, improve treatment response rates, and reduce the risk of adverse events associated with inappropriate therapy. POC molecular diagnostics facilitate real-time monitoring of disease progression, treatment response, and disease recurrence by measuring biomarker levels and genetic changes over time. By providing actionable diagnostic information at the point of care, POC molecular diagnostics support ongoing disease management strategies, enable early detection of treatment failure or disease relapse, and facilitate adjustments to treatment plans as needed. POC molecular diagnostics empower patients to take an active role in their healthcare decisions by providing access to personalized diagnostic information and treatment options. By involving patients in the decision-making process and tailoring treatment plans to their individual needs and preferences, POC molecular diagnostics enhance patient engagement, satisfaction, and adherence to therapy regimens. This factor will acceleate the demand of the Global Point-Of-Care Molecular Diagnostics Market.

Key Market Challenges

Quality Control and Assurance

POC molecular diagnostic tests are often performed in diverse settings, including clinics, physician offices, pharmacies, and remote locations with limited infrastructure. The variability in testing conditions, such as temperature, humidity, and operator skill level, can affect test performance and result accuracy. Unlike centralized laboratory testing, which is subject to stringent regulatory oversight and quality assurance protocols, POC molecular diagnostics may have less regulatory scrutiny and standardized quality control measures. This lack of uniformity in regulatory requirements and quality standards can lead to variability in test performance and result reliability across different POC testing platforms and devices. POC molecular diagnostic tests rely on high-quality sample collection and handling procedures to ensure accurate and reliable results. However, factors such as sample degradation, contamination, improper storage, and transportation can compromise sample integrity and affect test performance. Maintaining sample quality and stability is challenging in resource-limited or point-of-care settings where access to laboratory facilities and trained personnel may be limited. Developing robust molecular diagnostic assays for POC testing requires extensive optimization and validation to ensure analytical sensitivity, specificity, and reproducibility across diverse sample types and testing conditions. However, assay optimization and validation processes can be time-consuming, labor-intensive, and resource-intensive, posing challenges for manufacturers and developers of POC molecular diagnostic tests.

Infrastructure and Connectivity

POC molecular diagnostics are often deployed in settings where access to centralized laboratory facilities is limited or unavailable. This includes remote rural areas, underserved communities, and regions with inadequate healthcare infrastructure. The lack of laboratory infrastructure hinders the implementation and adoption of POC molecular diagnostic technologies. Many POC testing environments, such as clinics, field hospitals, and mobile healthcare units, operate in resource-limited settings with constrained financial, logistical, and technical resources. These settings may lack basic infrastructure such as reliable electricity, running water, and temperature-controlled storage, which are essential for performing molecular diagnostic tests safely and accurately. POC molecular diagnostic devices often require stable power sources to operate effectively. In regions with unreliable electricity grids or limited access to electricity, maintaining consistent power supply poses a significant challenge. Additionally, battery-operated devices may require frequent recharging or replacement, which can be impractical in resource-constrained settings. POC molecular diagnostic devices may rely on internet connectivity for data transmission, remote monitoring, and result reporting. However, internet infrastructure and connectivity can be unreliable or nonexistent in remote or rural areas, hindering real-time data exchange and communication between POC testing sites and healthcare facilities.

Key Market Trends

Miniaturization and Portability

Miniaturization and portability make molecular diagnostic technologies more accessible to a wider range of settings, including remote and resource-limited areas where access to centralized laboratory facilities may be limited or nonexistent. Portable POC devices can be deployed in clinics, field hospitals, community health centers, and even mobile healthcare units, bringing diagnostic testing closer to patients and improving healthcare access and equity. Miniaturized POC molecular diagnostic devices offer rapid testing capabilities, allowing for on-the-spot diagnosis and timely treatment decisions. With shorter turnaround times compared to traditional laboratory-based testing methods, portable POC devices enable healthcare providers to make real-time decisions about patient care, infection control, and public health interventions, particularly during outbreaks and emergencies. Miniaturized POC molecular diagnostic devices are designed for use at the point of care, where patients receive medical attention and treatment. These devices eliminate the need for sample transportation, centralized laboratory processing, and lengthy turnaround times associated with traditional testing methods, improving patient satisfaction, reducing healthcare costs, and enhancing overall workflow efficiency in point-of-care settings. Many miniaturized POC molecular diagnostic devices are compatible with mobile devices such as smartphones and tablets, enabling wireless connectivity, data transfer, and result reporting. Mobile integration allows healthcare providers to access and analyze diagnostic data in real time, track patient outcomes, and collaborate with colleagues remotely, enhancing clinical decision-making and care coordination.

Segmental Insights

Technology Insights

The Hybridization-Based segment is projected to experience rapid growth in the Global Point-Of-Care Molecular Diagnostics Market during the forecast period. Hybridization-based molecular diagnostic assays, such as nucleic acid hybridization and DNA microarrays, offer high sensitivity and specificity for the detection of nucleic acid targets. These assays enable the accurate identification and quantification of target sequences, making them suitable for a wide range of applications, including infectious disease diagnosis, genetic testing, and oncology. Hybridization-based assays support multiplexing, allowing simultaneous detection of multiple targets within a single reaction. This capability is particularly advantageous for diagnosing infectious diseases caused by multiple pathogens or identifying genetic mutations associated with complex diseases. Multiplex assays improve workflow efficiency, conserve sample volume, and reduce turnaround times in point-of-care settings. Hybridization-based assays are versatile and adaptable to different target molecules, including DNA, RNA, and proteins. They can be customized and optimized for specific applications and target sequences, making them suitable for diverse clinical and research purposes. Hybridization-based assays can also be integrated with various detection platforms, including microfluidic devices, biosensors, and portable instrumentation, enhancing their utility in point-of-care settings.

Application Insights

The Oncology segment is projected to experience rapid growth in the Global Point-Of-Care Molecular Diagnostics Market during the forecast period. There has been a significant rise in the incidence of cancer globally. Molecular diagnostics play a crucial role in cancer detection, prognosis, and treatment selection, which has driven the demand for point-of-care molecular diagnostic tools specifically designed for oncology applications. Timely and accurate diagnosis is critical for effective cancer treatment. Point-of-care molecular diagnostics offer the advantage of quick and precise testing at or near the patient, enabling faster diagnosis and treatment initiation. This is especially crucial in oncology, where early detection can significantly improve patient outcomes. There is a growing trend towards personalized medicine in oncology, where treatment decisions are tailored to individual patients based on their molecular profile. Point-of-care molecular diagnostics facilitate this approach by enabling real-time testing and immediate adjustment of treatment plans based on molecular findings.

Regional Insights

North America emerged as the dominant region in the Global Point-Of-Care Molecular Diagnostics Market in 2023. North America possesses advanced healthcare infrastructure, featuring well-established laboratory facilities, robust healthcare systems, and stringent regulatory frameworks. This infrastructure facilitates the development, validation, and adoption of point-of-care molecular diagnostics within the region. Renowned for its technological innovation, North America hosts numerous leading companies and research institutions actively engaged in advancing molecular diagnostic technologies. These entities drive growth in the point-of-care molecular diagnostics market by pioneering breakthroughs in molecular biology, microfluidics, and sensor technologies. North America serves as a focal point for significant investments in research and development (R&D) for healthcare technologies, particularly point-of-care molecular diagnostics. Funding from diverse sources, including government agencies, private investors, and venture capital firms, propels innovation and expedites the commercialization of new diagnostic products and platforms.

Key Market Players

Siemens Healthineers AG

Quidel Corporation

F. Hoffman-La Roche Ltd.

Danaher Corporation

Beckton & Dickinson Company

Trinity Biotech plc

Thermo Fisher Scientific Inc

bioMerieux S.A.

DiaSorin S.p.A

AccuBioTech Co., Ltd.

Report Scope:

In this report, the Global Point-Of-Care Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-Of-Care Molecular Diagnostics Market, By Technology:

PCR-based Genetic Sequencing-based Hybridization-based Microarray-based

Point-Of-Care Molecular Diagnostics Market, By Application:

Infectious Diseases Oncology Hematology Prenatal Testing Endocrinology Other

Point-Of-Care Molecular Diagnostics Market, By Test Location:

OTC POC

Point-Of-Care Molecular Diagnostics Market, By End User:

Decentralized Labs Hospitals Home-care Assisted Living Healthcare Facilities Others

Point-Of-Care Molecular Diagnostics Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-Of-Care Molecular Diagnostics Market.

Available Customizations:

Global Point-Of-Care Molecular Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point-Of-Care Molecular Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based)
  • 5.2.2. By Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, Other)
  • 5.2.3. By Test Location (OTC, POC)
  • 5.2.4. By End User (Decentralized Labs, Hospitals, Home-care, Assisted Living Healthcare Facilities, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map

6. North America Point-Of-Care Molecular Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Test Location
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Point-Of-Care Molecular Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Test Location
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Point-Of-Care Molecular Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Test Location
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Point-Of-Care Molecular Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Test Location
      • 6.3.3.2.4. By End User

7. Europe Point-Of-Care Molecular Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Test Location
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Test Location
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Test Location
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Test Location
      • 7.3.3.2.4. By End User
  • 7.3.4. France Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Test Location
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Test Location
      • 7.3.5.2.4. By End User

8. Asia-Pacific Point-Of-Care Molecular Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Test Location
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Test Location
      • 8.3.1.2.4. By End User
  • 8.3.2. India Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Test Location
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Test Location
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Test Location
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Test Location
      • 8.3.5.2.4. By End User

9. South America Point-Of-Care Molecular Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Test Location
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Point-Of-Care Molecular Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Test Location
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Point-Of-Care Molecular Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Test Location
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Point-Of-Care Molecular Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Test Location
      • 9.3.3.2.4. By End User

10. Middle East and Africa Point-Of-Care Molecular Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Test Location
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Point-Of-Care Molecular Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Test Location
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Point-Of-Care Molecular Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Test Location
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Point-Of-Care Molecular Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Test Location
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Point-Of-Care Molecular Diagnostics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Siemens Healthineers AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Product & Service Offerings
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel
  • 14.1.7. SWOT Analysis
• 14.2. Quidel Corporation
• 14.3. F. Hoffman-La Roche Ltd.
• 14.4. Danaher Corporation
• 14.5. Beckton & Dickinson Company
• 14.6. Trinity Biotech plc
• 14.7. Thermo Fisher Scientific Inc
• 14.8. bioMerieux S.A.
• 14.9. DiaSorin S.p.A
• 14.10.AccuBioTech Co., Ltd

15. Strategic Recommendations

16. About Us & Disclaimer